Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 56% Improvement Relative Risk HCQ for COVID-19  Ly et al.  EARLY TREATMENT Is early treatment with HCQ + AZ beneficial for COVID-19? Retrospective 226 patients in France Lower mortality with HCQ + AZ (p=0.02) c19hcq.org Ly et al., Int. J. Antimicrobial Agents, Aug 2020 Favors HCQ Favors control

Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020

Ly et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219 (date from preprint)
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
Retrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0.37, p=0.02. 1,690 elderly residents (mean age 83), 226 infected residents, 116 treated with HCQ+AZ >= 3 days.
Detection via mass screening also showed significant improvements (16.9% vs. 40.6%, OR 0.20, p=0.001), suggesting that earlier detection and treatment is more successful.
risk of death, 55.6% lower, RR 0.44, p = 0.02, treatment 18 of 116 (15.5%), control 29 of 110 (26.4%), NNT 9.2, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ly et al., 21 Aug 2020, retrospective, France, peer-reviewed, mean age 83.0, 21 authors, dosage 200mg tid days 1-10, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020
Tran Duc Anh Ly, Didier Zanini, Vincent Laforge, Sylvie Arlotto, Stephanie Gentile, Helene Mendizabal, Michael Finaud, David Morel, Olivier Quenette, Priscilla Malfuson-Clot-Faybesse, Alain Midejean, Phuc Le-Dinh, Gérard Daher, Berengere Labarriere, Anne-Marie Morel-Roux, Alain Coquet, Patrick Augier, Philippe Parola, Eric Chabriere, Didier Raoult, Philippe Gautret
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219
Objectives: This study aimed to report the results of SARS-CoV-2 PCR-based screening campaigns conducted on dependent elderly residents (compared with staff members) in long-term care facilities (LTCFs) in Marseille, France, and the follow-up of positive cases. Methods: Data from 1691 elderly residents and 10 0 0 members of staff were retrospectively collected through interviewing the medical teams in 24 LTCFs and using the hospitals' electronic health recording systems.
Declarations Competing Interests: No potential conflict of interest relevant to this article was reported. Ethical Approval: Ethical approval was obtained from the Marseille Institutional Review Board and Ethics Committee (N °2020-028).
References
Amrane, Tissot-Dupont, Doudier, Eldin, Hocquart et al., Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, -January 31 st to March 1 st , 2020: A respiratory virus snapshot, Travel Med Infect Dis
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Ayerbe, Risco-Risco, Ayis, The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients, Intern Emerg Med, doi:10.1007/s11739-020-02505-x
Belmin, Um-Din, Donadio, Magri, Nghiem et al., Coronavirus Disease 2019 Outcomes in French Nursing Homes That Implemented Staff Confinement With Residents, JAMA Netw Open
Blain, Rolland, Benetos, Giacosa, Albrand et al., Atypical clinical presentation of COVID-19 infection in residents of a long-term care facility, Eur Geriatr Med, doi:10.1007/s41999-020-00352-9
Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.penalty-@M106144
Comas-Herrera, Zalakain, Lemmon, Henderson, Litwin et al., Updated report: Updated international report on COVID-19 related mortality in care homes
Covid-, Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study, Eur J Intern Med, doi:10.1016/j.ejim.2020.penalty-@M08.019
Danis, Fonteneau, Georges, Daniau, Bernard-Stoecklin et al., High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020, Euro Surveill
Dauby, Bottieau, The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.032
Davido, Lansaman, Bessis, Alvarez, Bouchand et al., Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time, Int J Antimicrob Agents Oct, doi:10.1016/j.ijantimicag.2020.106129
Etard, Vanhems, Atlani-Duault, Ecochard, Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020, Euro Surveill
Fisman, Bogoch, Lapointe-Shaw, Mccready, Tuite, Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.15957
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial, Int J Antimicrob Agents
Gentry, Humphrey, Thind, Hendrickson, Kurdgelashvili et al., Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30305-2
Heras, Garibaldi, Boix, Valero, Castillo et al., COVID-19 mortality risk factors in older people in a long-term care center. Research square
Hewitt, Carter, Vilches-Moraga, Quinn, Braude et al., The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study, Lancet Public Health, doi:10.1016/S2468-2667(20)30146-8
Hoxha, Wyndham-Thomas, Klamer, Dubourg, Vermeulen et al., Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30560-0
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Louie, Scott, Dubois, Sturtz, Lu et al., Lessons from mass-testing for COVID-19 in long-term care facilities for the elderly in San Francisco, Clin Infect Dis
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Moraes, Viana, Resende, Vasconcellos, Moura et al., COVID-19 in long-term care facilities for the elderly: laboratory screening and disease dissemination prevention strategies, Cien Saude Colet, doi:10.1590/1413-81232020259.20382020
Opensafely, Elizabeth, Alex, Krishnan, Seb et al., OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients, doi:10.1101/2020.05.06.20092999v1
St, Santé Publique France
Zou, Dai, Zhang, Zhang, Zhang, Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19, Arch Pharm Res
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit